EMPLOYMENT AGREEMENTEmployment Agreement • February 28th, 2012 • Impax Laboratories Inc • Pharmaceutical preparations • Delaware
EMPLOYMENT AGREEMENT (“Agreement”), entered into as of May 2, 2011 (the “Effective Date”), by and between Impax Laboratories, Inc., a Delaware corporation (the “Company”), and Mark Schlossberg (the “Executive”).
FIRST AMENDMENT OF THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • February 28th, 2012 • Impax Laboratories Inc • Pharmaceutical preparations • Delaware
This FIRST AMENDMENT OF THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (THIS “First Amendment”) is made and effective as of December 23, 2011 (the “First Amendment Effective Date”) by and between IMPAX LABORATORIES, INC., a Delaware corporation with its principal place of business at 30831 Huntwood Avenue, Hayward, CA 94544 (“Impax”), and GLAXO GROUP LIMITED, a company organized and existing under the laws of England and having an office and place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, United Kingdom (“GSK”).
AMENDMENT TO LICENSE AND DISTRIBUTION AGREEMENTLicense and Distribution Agreement • February 28th, 2012 • Impax Laboratories Inc • Pharmaceutical preparations
This Amendment to License and Distribution Agreement (this “Amendment”) is dated as of March 1, 2010 by and between Shire LLC, a Kentucky company with offices located at 9200 Brookfield Court, Florence, KY 41042 (“Shire”), and Impax Laboratories, Inc., a Delaware corporation with offices located at 30831 Huntwood Ave., Hayward, CA 94544 (“Impax”). Shire and Impax are collectively referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO JOINT DEVELOPMENT AGREEMENT DATED NOVEMBER 26, 2008Joint Development Agreement • February 28th, 2012 • Impax Laboratories Inc • Pharmaceutical preparations
This FIRST AMENDMENT to the Joint Development Agreement dated November 26, 2008 (this “First Amendment”) is effective as of the date of last signature (“Amendment Effective Date”) and is made and entered into by and between Impax Laboratories, Inc., a Delaware corporation, with its principal place of business at 30831 Huntwood Avenue, Hayward, California 94544 (“Impax”) and Medicis Pharmaceutical Corporation, a corporation organized under the laws of the State of Delaware, with its principal place of business at 7720 North Dobson Road, Scottsdale, Arizona, 85256 (“Medicis”).
